-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
POINT Biopharma Global Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2021 to Q3 2023.
- POINT Biopharma Global Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2023 was -$25.1M, a 3.53% decline year-over-year.
- POINT Biopharma Global Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2023 was $95.7M.
- POINT Biopharma Global Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $97.8M.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)